You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Combination Chemo and Radiolabeled Monoclonal Antibody

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Cancer Trial in New York (90Y-hu3S193, 111In-hu3S193)

Completed
Has Results
  • Ovarian Cancer
  • 90Y-hu3S193
  • 111In-hu3S193
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Kidney Cancer Trial in New York (Iodine-131 radiolabeled chimeric mAb G250 (131I-cG250))

Completed
Has Results
  • Kidney Cancer
  • Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Colorectal Cancer Trial in Hangzhou (Ametumumab, Anti-PD-1 mAb, Cetuximab)

Not yet recruiting
  • Colorectal Cancer
  • Hangzhou, Zhejiang, China
    Sir Run Run Shaw Hospital, Zhejiang University School of Medicin
Jan 30, 2023

Solid Tumors Trial (GS-9911, Zimberelimab)

Not yet recruiting
  • Solid Tumors
  • (no location specified)
Oct 9, 2023

Recurrent Adult Hodgkin Lymphoma Trial in Duarte (biological, drug, other, procedure)

Active, not recruiting
  • Recurrent Adult Hodgkin Lymphoma
  • basiliximab
  • +8 more
  • Duarte, California
    City of Hope Medical Center
Mar 17, 2022

Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

Not yet recruiting
  • Multiple Cancer
  • Colorectal Cancer
  • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
  • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
  • (no location specified)
Aug 20, 2023

Solid Tumor Trial (GS-4528, Zimberelimab)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Apr 21, 2023

Lymphoma Trial (BYON4228 + Rituximab)

Not yet recruiting
  • Lymphoma
  • BYON4228 + Rituximab
  • (no location specified)
Feb 20, 2023

Salivary Gland Cancer Trial (vedicitumomab (Edisil, RC48), vedicitumomab in combination with pyrrolizidine, RC48 in combination

Not yet recruiting
  • Salivary Gland Cancer
  • vedicitumomab (Edisil, RC48）
  • +3 more
  • (no location specified)
Jun 9, 2023

Renal Cell Carcinoma, Kidney Tumor, Renal Cancer Trial in New York (Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250))

Completed
Has Results
  • Renal Cell Carcinoma
  • +3 more
  • Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250)
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Cancer, Tumor, Solid, Malignant Tumor Trial (OR502, Cemiplimab)

Not yet recruiting
  • Cancer
  • +6 more
  • (no location specified)
Oct 16, 2023

HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer Trial in Palo Alto (Utomilumab, Trastuzumab,

Completed
Has Results
  • HER2 Positive Breast Carcinoma
  • +6 more
  • Palo Alto, California
    Stanford University, School of Medicine
Sep 22, 2022

Prostate Cancer Trial in United States (177Lu-J591, Ketoconazole, Hydrocortisone)

Active, not recruiting
  • Prostate Cancer
  • Los Angeles, California
  • +8 more
Mar 25, 2022

Solid Tumor, Adult Trial in Australia (IOS-1002, IOS-1002 + PD-1 mAb)

Recruiting
  • Solid Tumor, Adult
  • Clayton, Australia
  • +4 more
Mar 15, 2023

Solid Tumor Trial (IN10018, Nab-paclitaxel, Tislelizumab)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Aug 1, 2023

HIV Trial in United States (PGT121.414.LS, VRC07-523LS)

Completed
  • HIV Infections
  • PGT121.414.LS
  • VRC07-523LS
  • Los Angeles, California
  • +4 more
Jan 31, 2023

Patients With Advanced Solid Tumors Trial in Shanghai (ICP-189)

Not yet recruiting
  • Patients With Advanced Solid Tumors
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
May 8, 2022

Recurrent DLBCL, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory DLBCL Trial in United States (drug, other, biological)

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +5 more
  • Duarte, California
  • +3 more
Nov 17, 2022

Advanced Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Trial in Boston (AGEN1423,

Not yet recruiting
  • Advanced Pancreatic Ductal Adenocarcinoma
  • +2 more
  • Boston, Massachusetts
    Beth Israel Deaconess Medical Center
Nov 18, 2022

Tumor Trial in Chuo-Ku, Kashiwa (JNJ-63723283, Erdafitinib)

Completed
  • Neoplasm
  • Chuo-Ku, Japan
  • +1 more
Nov 3, 2022

Advanced Unresectable Solid Tumors Trial in Beijing (M108)

Recruiting
  • Advanced Unresectable Solid Tumors
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Jul 25, 2022

Solid Tumor, Adult Trial in United States (FT538, Cyclophosphamide, Fludarabine)

Recruiting
  • Solid Tumor, Adult
  • Hackensack, New Jersey
  • +3 more
Apr 14, 2022

Advanced Solid Tumors Trial in Beijing (BMS-986213)

Recruiting
  • Advanced Solid Tumors
  • Beijing, Beijing, China
  • +1 more
Nov 21, 2022

Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +4 more
  • Necitumumab
  • +4 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Jan 5, 2023

Moderate to Severe Active Rheumatoid Arthritis Trial in Beijing (HS628+MTX, Actemra +MTX)

Completed
  • Moderate to Severe Active Rheumatoid Arthritis
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Sep 14, 2023